ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P22681


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name CBL_HUMAN
Primary accession number P22681
Secondary accession numbers None
Integrated into Swiss-Prot on August 1, 1991
Sequence was last modified on August 1, 1991 (Sequence version 1)
Annotations were last modified on    November 25, 2008 (Entry version 112)
Name and origin of the protein
Protein name E3 ubiquitin-protein ligase CBL
Synonyms EC 6.3.2.-
Signal transduction protein CBL
Proto-oncogene c-CBL
Casitas B-lineage lymphoma proto-oncogene
RING finger protein 55
Gene name
Name: CBL
Synonyms: CBL2, RNF55
From
Homo sapiens (Human) [TaxID: 9606] 
Taxonomy Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=2030914 [NCBI, ExPASy, EBI, Israel, Japan]
Blake T.J., Shapiro M., Morse H.C. III, Langdon W.Y.;
"The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.";
Oncogene 6:653-657(1991).
[2]
FUNCTION.
DOI=10.1126/science.286.5438.309; PubMed=10514377 [NCBI, ExPASy, EBI, Israel, Japan]
Joazeiro C.A., Wing S.S., Huang H.-K., Leverson J.D., Hunter T., Liu Y.-C.;
"The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.";
Science 286:309-312(1999).
[3]
PHOSPHORYLATION BY EGFR.
DOI=10.1074/jbc.270.35.20242; PubMed=7657591 [NCBI, ExPASy, EBI, Israel, Japan]
Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.;
"Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation.";
J. Biol. Chem. 270:20242-20245(1995).
[4]
INTERACTION WITH ZAP70.
DOI=10.1074/jbc.272.52.33140; PubMed=9407100 [NCBI, ExPASy, EBI, Israel, Japan]
Lupher M.L. Jr., Songyang Z., Shoelson S.E., Cantley L.C., Band H.;
"The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70.";
J. Biol. Chem. 272:33140-33144(1997).
[5]
PHOSPHORYLATION BY SYK AND FYN.
DOI=10.1074/jbc.273.15.8867; PubMed=9535867 [NCBI, ExPASy, EBI, Israel, Japan]
Deckert M., Elly C., Altman A., Liu Y.C.;
"Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases.";
J. Biol. Chem. 273:8867-8874(1998).
[6]
INTERACTION WITH LAT2.
DOI=10.1084/jem.20021405; PubMed=12486104 [NCBI, ExPASy, EBI, Israel, Japan]
Brdicka T., Imrich M., Angelisova P., Brdickova N., Horvath O., Spicka J., Hilgert I., Luskova P., Draber P., Novak P., Engels N., Wienands J., Simeoni L., Oesterreicher J., Aguado E., Malissen M., Schraven B., Horejsi V.;
"Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling.";
J. Exp. Med. 196:1617-1626(2002).
[7]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-669 AND TYR-674, AND MASS SPECTROMETRY.
DOI=10.1073/pnas.2436191100; PubMed=12522270 [NCBI, ExPASy, EBI, Israel, Japan]
Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
"Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.";
Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
[8]
INTERACTION WITH SH2B2.
DOI=10.1038/sj/leu/2401397; PubMed=10374881 [NCBI, ExPASy, EBI, Israel, Japan]
Wakioka T., Sasaki A., Mitsui K., Yokouchi M., Inoue A., Komiya S., Yoshimura A.;
"APS, an adaptor protein containing pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl.";
Leukemia 13:760-767(1999).
[9]
INTERACTION WITH SH2B2.
DOI=10.1038/sj.onc.1202326; PubMed=9989826 [NCBI, ExPASy, EBI, Israel, Japan]
Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.;
"APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis.";
Oncogene 18:759-767(1999).
[10]
INTERACTION WITH SLA AND ZAP70, AND MUTAGENESIS OF GLY-306.
DOI=10.1073/pnas.96.17.9775; PubMed=10449770 [NCBI, ExPASy, EBI, Israel, Japan]
Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
"SLAP, a dimeric adapter protein, plays a functional role in T cell receptor signaling.";
Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
[11]
INTERACTION WITH SLA2.
DOI=10.1084/jem.194.9.1263; PubMed=11696592 [NCBI, ExPASy, EBI, Israel, Japan]
Holland S.J., Liao X.C., Mendenhall M.K., Zhou X., Pardo J., Chu P., Spencer C., Fu A.C., Sheng N., Yu P., Pali E., Nagin A., Shen M., Yu S., Chan E., Wu X., Li C., Woisetschlager M., Aversa G., Kolbinger F., Bennett M.K., Molineaux S., Luo Y., Payan D.G., Mancebo H.S.Y., Wu J.;
"Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel inhibitor of antigen receptor signaling.";
J. Exp. Med. 194:1263-1276(2001).
[12]
INTERACTION WITH CD2AP.
DOI=10.1074/jbc.M005784200; PubMed=11067845 [NCBI, ExPASy, EBI, Israel, Japan]
Kirsch K.H., Georgescu M.M., Shishido T., Langdon W.Y., Birge R.B., Hanafusa H.;
"The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain interaction.";
J. Biol. Chem. 276:4957-4963(2001).
[13]
INTERACTION WITH SH2B2, MUTAGENESIS OF TYR-371; TYR-700; TYR-731 AND TYR-774, AND PHOSPHORYLATION AT TYR-371; TYR-700 AND TYR-774.
DOI=10.1128/MCB.22.11.3599-3609.2002; PubMed=11997497 [NCBI, ExPASy, EBI, Israel, Japan]
Liu J., Kimura A., Baumann C.A., Saltiel A.R.;
"APS facilitates c-Cbl tyrosine phosphorylation and GLUT4 translocation in response to insulin in 3T3-L1 adipocytes.";
Mol. Cell. Biol. 22:3599-3609(2002).
[14]
INTERACTION WITH INPPL1.
DOI=10.1016/S0006-291X(02)02894-2; PubMed=12504111 [NCBI, ExPASy, EBI, Israel, Japan]
Vandenbroere I., Paternotte N., Dumont J.E., Erneux C., Pirson I.;
"The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-containing inositol polyphosphate 5-phosphatase SHIP2.";
Biochem. Biophys. Res. Commun. 300:494-500(2003).
[15]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-371 AND TYR-552, AND MASS SPECTROMETRY.
TISSUE=Epithelium;
DOI=10.1074/mcp.M500089-MCP200; PubMed=15951569 [NCBI, ExPASy, EBI, Israel, Japan]
Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J., Lauffenburger D.A., White F.M.;
"Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules.";
Mol. Cell. Proteomics 4:1240-1250(2005).
[16]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-674, AND MASS SPECTROMETRY.
DOI=10.1038/nbt1046; PubMed=15592455 [NCBI, ExPASy, EBI, Israel, Japan]
Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., Zha X.-M., Polakiewicz R.D., Comb M.J.;
"Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
Nat. Biotechnol. 23:94-101(2005).
[17]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667 AND SER-675, AND MASS SPECTROMETRY.
TISSUE=T-cell;
DOI=10.1038/nmeth776; PubMed=16094384 [NCBI, ExPASy, EBI, Israel, Japan]
Tao W.A., Wollscheid B., O'Brien R., Eng J.K., Li X.-J., Bodenmiller B., Watts J.D., Hood L., Aebersold R.;
"Quantitative phosphoproteome analysis using a dendrimer conjugation chemistry and tandem mass spectrometry.";
Nat. Methods 2:591-598(2005).
[18]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-900, AND MASS SPECTROMETRY.
TISSUE=Epithelium;
DOI=10.1038/nbt1240; PubMed=16964243 [NCBI, ExPASy, EBI, Israel, Japan]
Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
"A probability-based approach for high-throughput protein phosphorylation analysis and site localization.";
Nat. Biotechnol. 24:1285-1292(2006).
[19]
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 47-350, CALCIUM-BINDING SITE, AND MUTAGENESIS OF SER-80; PRO-82; ASP-229; GLU-240; ARG-294 AND GLY-306.
DOI=10.1038/18050; PubMed=10078535 [NCBI, ExPASy, EBI, Israel, Japan]
Meng W., Sawasdikosol S., Burakoff S.J., Eck M.J.;
"Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase.";
Nature 398:84-90(1999).
[20]
X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 47-434 IN COMPLEX WITH ZAP70 AND UBE2L3.
DOI=10.1016/S0092-8674(00)00057-X; PubMed=10966114 [NCBI, ExPASy, EBI, Israel, Japan]
Zheng N., Wang P., Jeffrey P.D., Pavletich N.P.;
"Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases.";
Cell 102:533-539(2000).
Comments
  • FUNCTION: Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
  • PATHWAY: Protein modification; protein ubiquitination.
  • SUBUNIT: Associates with NCK via its SH3 domain. The phosphorylated C-terminus interacts with CD2AP via its second SH3 domain. Binds to UBE2L3. Interacts with adapters SLA, SLA2 and with the phosphorylated C-terminus of SH2B2. Interacts with EGFR, SYK and ZAP70 via the highly conserved Cbl-N region. Also interacts with SORBS1 and INPPL1/SHIP2. Interacts with phosphorylated LAT2. May interact with CBLB (By similarity).
  • INTERACTION:
    P00533:EGFR; NbExp=1; IntAct=EBI-518228, EBI-297353;
    Q07666:KHDRBS1; NbExp=1; IntAct=EBI-518228, EBI-1364;
  • SUBCELLULAR LOCATION: Cytoplasm.
  • DOMAIN: The RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
  • DOMAIN: The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
  • PTM: Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
  • DISEASE: Can be converted to an oncogenic protein by deletions or mutations that disturb its ability to down-regulate RTKs.
  • MISCELLANEOUS: This protein has one functional calcium-binding site.
  • SIMILARITY: Contains 1 CBL N-terminal domain.
  • SIMILARITY: Contains 2 EF-hand-like domains.
  • SIMILARITY: Contains 1 RING-type zinc finger.
  • SIMILARITY: Contains 1 SH2 domain.
  • SIMILARITY: Contains 1 UBA domain.
  • WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/CBLID171.html";.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
X57110; CAA40393.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
PIR A43817; A43817.
RefSeq NP_005179.2; -.
UniGene Hs.504096
3D structure databases
PDB
1B47; X-ray; 2.20 A; A/B/C=47-350.[ExPASy / RCSB / EBI]
1FBV; X-ray; 2.90 A; A=47-434.[ExPASy / RCSB / EBI]
1YVH; X-ray; 2.05 A; A=23-351.[ExPASy / RCSB / EBI]
2CBL; X-ray; 2.10 A; A=47-351.[ExPASy / RCSB / EBI]
2JUJ; NMR; -; A=851-906.[ExPASy / RCSB / EBI]
2OO9; X-ray; 2.10 A; A/B/C=856-899.[ExPASy / RCSB / EBI]
3BUM; X-ray; 2.00 A; B=23-351.[ExPASy / RCSB / EBI]
3BUN; X-ray; 2.00 A; B=23-351.[ExPASy / RCSB / EBI]
3BUO; X-ray; 2.60 A; B/D=23-351.[ExPASy / RCSB / EBI]
3BUW; X-ray; 1.45 A; B/D=23-351.[ExPASy / RCSB / EBI]
3BUX; X-ray; 1.35 A; B/D=23-351.[ExPASy / RCSB / EBI]
Detailed list of linked structures.
PDBsum 1B47; -.
1FBV; -.
1YVH; -.
2CBL; -.
2JUJ; -.
2OO9; -.
3BUM; -.
3BUN; -.
3BUO; -.
3BUW; -.
3BUX; -.
ModBase P22681.
Protein-protein interaction databases
DIP DIP:189N; -.
IntAct P22681; -.
PTM databases
PhosphoSite P22681; -.
Organism-specific databases
H-InvDB HIX0010191; -.
HGNC HGNC:1541; CBL.
GenAtlas CBL.
HPA CAB004350; -.
MIM 165360; gene. [NCBI / EBI]
PharmGKB PA26115; -.
GeneCards P22681.
Gene expression databases
ArrayExpress P22681; -.
CleanEx HS_CBL; -.
GermOnline ENSG00000110395; Homo sapiens.
Ontologies
GO
GO:0005829; Cellular component: cytosol (inferred from experiment from Reactome).
GO:0005634; Cellular component: nucleus (inferred from electronic annotation from InterPro).
GO:0005886; Cellular component: plasma membrane (inferred from direct assay from HGNC).
GO:0005509; Molecular function: calcium ion binding (inferred from electronic annotation from InterPro).
GO:0005515; Molecular function: protein binding (inferred from physical interaction from UniProtKB).
GO:0004871; Molecular function: signal transducer activity (inferred from electronic annotation from InterPro).
GO:0003700; Molecular function: transcription factor activity (traceable author statement from ProtInc).
GO:0004842; Molecular function: ubiquitin-protein ligase activity (traceable author statement from HGNC).
GO:0008270; Molecular function: zinc ion binding (inferred from electronic annotation from InterPro).
GO:0007173; Biological process: epidermal growth factor receptor signaling pathway (traceable author statement from HGNC).
GO:0048260; Biological process: positive regulation of receptor-mediated endocytosis (traceable author statement from HGNC).
GO:0016567; Biological process: protein ubiquitination (traceable author statement from HGNC).
GO:0006511; Biological process: ubiquitin-dependent protein catabolic process (inferred from electronic annotation from UniProtKB-KW).
QuickGo view.
Family and domain databases
InterPro IPR014741; Adaptor_Cbl_EF_Hand-like.
IPR003153; Adaptor_Cbl_N.
IPR014742; Adaptor_Cbl_SH2-like.
IPR011992; EF-Hand_type.
IPR000980; SH2.
IPR000449; UBA/transl_elong_EF1B_N.
IPR015940; UBA/transl_elong_EF1B_N_euk.
IPR001841; Znf_RING.
IPR013083; Znf_RING/FYVE/PHD.
Graphical view of domain structure.
Gene3D G3DSA:1.20.930.20; Adaptor_Cbl_N; 1.
G3DSA:1.10.238.10; EF-Hand_type; 1.
G3DSA:3.30.40.10; Znf_RING/FYVE/PHD; 1.
Pfam PF02262; Cbl_N; 1.
PF02761; Cbl_N2; 1.
PF02762; Cbl_N3; 1.
PF00627; UBA; 1.
PF00097; zf-C3HC4; 1.
Pfam graphical view of domain structure.
SMART SM00184; RING; 1.
SM00165; UBA; 1.
SMART graphical view of domain structure.
PROSITE PS50001; SH2; FALSE_NEG.
PS50030; UBA; 1.
PS00518; ZF_RING_1; 1.
PS50089; ZF_RING_2; 1.
PROSITE graphical view of domain structure (profiles).
ProtoNet P22681.
Genome annotation databases
Ensembl ENSG00000110395; Homo sapiens. [Contig view]
GeneID 867; -.
KEGG hsa:867; -.
Phylogenomic databases
HOGENOM P22681; -.
HOVERGEN P22681; -.
Other
LinkHub P22681; -.
NextBio 3618; -.
SOURCE CBL; Homo sapiens.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Calcium; Cytoplasm; Ligase; Metal-binding; Phosphoprotein; Proto-oncogene; Repeat; SH2 domain; Ubl conjugation pathway; Zinc; Zinc-finger.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom   To Length Description FTId
CHAIN   1   906  906     E3 ubiquitin-protein ligase CBL. PRO_0000055858
DOMAIN   46   357  312     CBL N-terminal. 
DOMAIN   212   220  9     EF-hand-like 1. 
DOMAIN   229   240  12     EF-hand-like 2. 
DOMAIN   267   341  75     SH2; atypical. 
DOMAIN   856   895  40     UBA. 
ZN_FING   381   420  40     RING-type. 
REGION   46   177  132     4H. 
REGION   342   380  39     Linker. 
REGION   648   906  259     Interaction with CD2AP. 
COMPBIAS   357   476  120     Asp/Glu-rich (acidic). 
COMPBIAS   477   688  212     Pro-rich. 
COMPBIAS   689   834  146     Asp/Glu-rich (acidic). 
BINDING   294   294        Phosphotyrosine (By similarity). 
MOD_RES   371   371        Phosphotyrosine; by INSR. 
MOD_RES   552   552        Phosphotyrosine. 
MOD_RES   667   667        Phosphoserine. 
MOD_RES   668   668        Phosphoserine (By similarity). 
MOD_RES   669   669        Phosphoserine. 
MOD_RES   674   674        Phosphotyrosine. 
MOD_RES   675   675        Phosphoserine. 
MOD_RES   700   700        Phosphotyrosine. 
MOD_RES   774   774        Phosphotyrosine. 
MOD_RES   900   900        Phosphoserine. 
MUTAGEN   80    80        S->D: Abolishes interaction with ZAP70. 
MUTAGEN   82    82        P->A: Abolishes interaction with ZAP70. 
MUTAGEN   229   229        D->Q: Abolishes interaction with ZAP70. 
MUTAGEN   240   240        E->S: Abolishes interaction with ZAP70. 
MUTAGEN   294   294        R->K: Abolishes interaction with ZAP70. 
MUTAGEN   306   306        G->E: Abolishes interaction with ZAP70, but does not affect interaction with SLA. 
MUTAGEN   371   371        Y->F: Strongly reduces tyrosine phosphorylation by INSR; when associated with F-700 and F-774. 
MUTAGEN   700   700        Y->F: Strongly reduces tyrosine phosphorylation by INSR; when associated with F-371 and F-774. 
MUTAGEN   731   731        Y->F: No effect on tyrosine phosphorylation by INSR. 
MUTAGEN   774   774        Y->F: Strongly reduces tyrosine phosphorylation by INSR; when associated with F-371 and F-700. 
HELIX   53    70  18      
HELIX   73    75  3      
HELIX   84   101  18      
HELIX   106   111  6      
HELIX   113   136  24      
HELIX   137   141  5      
HELIX   146   168  23      
HELIX   170   172  3      
HELIX   176   178  3      
HELIX   184   194  11      
STRAND   198   201  4      
HELIX   202   210  9      
HELIX   218   228  11      
STRAND   233   237  5      
HELIX   238   247  10      
HELIX   251   253  3      
HELIX   254   261  8      
HELIX   274   281  8      
HELIX   282   284  3      
STRAND   290   295  6      
STRAND   297   299  3      
STRAND   302   308  7      
STRAND   314   317  4      
STRAND   320   322  3      
HELIX   324   333  10      
STRAND   354   356  3      
HELIX   365   372  8      
TURN   382   384  3      
STRAND   385   388  4      
STRAND   394   396  3      
HELIX   402   410  9      
TURN   417   419  3      
HELIX   856   866  11      
HELIX   871   880  10      
TURN   881   883  3      
HELIX   885   895  11      
Sequence information
Length: 906 AA [This is the length of the unprocessed precursor] Molecular weight: 99647 Da [This is the MW of the unprocessed precursor] CRC64: 7D686B050204AD8F [This is a checksum on the sequence]
        10         20         30         40         50         60 
MAGNVKKSSG AGGGTGSGGS GSGGLIGLMK DAFQPHHHHH HHLSPHPPGT VDKKMVEKCW 

        70         80         90        100        110        120 
KLMDKVVRLC QNPKLALKNS PPYILDLLPD TYQHLRTILS RYEGKMETLG ENEYFRVFME 

       130        140        150        160        170        180 
NLMKKTKQTI SLFKEGKERM YEENSQPRRN LTKLSLIFSH MLAELKGIFP SGLFQGDTFR 

       190        200        210        220        230        240 
ITKADAAEFW RKAFGEKTIV PWKSFRQALH EVHPISSGLE AMALKSTIDL TCNDYISVFE 

       250        260        270        280        290        300 
FDIFTRLFQP WSSLLRNWNS LAVTHPGYMA FLTYDEVKAR LQKFIHKPGS YIFRLSCTRL 

       310        320        330        340        350        360 
GQWAIGYVTA DGNILQTIPH NKPLFQALID GFREGFYLFP DGRNQNPDLT GLCEPTPQDH 

       370        380        390        400        410        420 
IKVTQEQYEL YCEMGSTFQL CKICAENDKD VKIEPCGHLM CTSCLTSWQE SEGQGCPFCR 

       430        440        450        460        470        480 
CEIKGTEPIV VDPFDPRGSG SLLRQGAEGA PSPNYDDDDD ERADDTLFMM KELAGAKVER 

       490        500        510        520        530        540 
PPSPFSMAPQ ASLPPVPPRL DLLPQRVCVP SSASALGTAS KAASGSLHKD KPLPVPPTLR 

       550        560        570        580        590        600 
DLPPPPPPDR PYSVGAESRP QRRPLPCTPG DCPSRDKLPP VPSSRLGDSW LPRPIPKVPV 

       610        620        630        640        650        660 
SAPSSSDPWT GRELTNRHSL PFSLPSQMEP RPDVPRLGST FSLDTSMSMN SSPLVGPECD 

       670        680        690        700        710        720 
HPKIKPSSSA NAIYSLAARP LPVPKLPPGE QCEGEEDTEY MTPSSRPLRP LDTSQSSRAC 

       730        740        750        760        770        780 
DCDQQIDSCT YEAMYNIQSQ APSITESSTF GEGNLAAAHA NTGPEESENE DDGYDVPKPP 

       790        800        810        820        830        840 
VPAVLARRTL SDISNASSSF GWLSLDGDPT TNVTEGSQVP ERPPKPFPRR INSERKAGSC 

       850        860        870        880        890        900 
QQGSGPAASA ATASPQLSSE IENLMSQGYS YQDIQKALVI AQNNIEMAKN ILREFVSISS 


PAHVAT 

P22681 in FASTA format

View entry in original UniProtKB/Swiss-Prot format
View entry in raw text format (no links)
Report form for errors/updates in this UniProtKB/Swiss-Prot entry